Antimicrobial Resistance (AMR)
The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.
From STEDI to STRIDES: Valuing broader health-system benefits of AMR diagnostics
21 July 2025
Antimicrobial resistance (AMR) is an urgent global health crisis. AMR infections cause an estimated 1.3 million deaths globally every year, and this number is only projected to rise.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…
R&D for new drugs to tackle AMR is a high-return investment for all EU member states
19 July 2024
Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
The European Commission and European Parliament have set out their proposals for a reformed EU pharmaceutical legislation which could substantially change the incentive ecosystem for the first time in 20 years.
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
This is part 2 of the insight series which explores how progress towards an effective pull incentive for antibiotics can be made in Europe.
